Well, it certainly looks like Cholestech mean business, they have identified and indeed experienced the potential revenue generation that diagnosing and monitoring two major diseases can bring, those diseases (Heart Disease and Diabetes) are set to provide (unfortunately) unprecedented growth long out into the future.
It is my belief that Cholestech have been actively involved in assessing G5? Also Cholestech has groomed the market to expect acquisitions of products/technology. I previously reported that Provalis were actively seeking a deal where by the marketing partner would pay a license fee and shoulder any further R&D, and I believe this may include MicroG, as it is based around the Glycosal technology?
Reading between the lines MicroG would be able to test BOTH A1c and Glucose, and be the ONLY product capable of such a combination for home testing. IF my analysis is correct MicroG would very quickly gain market share from existing Glucose tests, which World Wide is truely massive. The expected launch date for MicroG is 2005/06, however, with the correct maketing partner R&D could see a renewed vigour and revised launch date?
Provalis' technology and products have caught the eye of the diabetes industry, and IN MY OPINION ONLY it is when and with who we will see a deal and not if.
Please conduct your own research before buying shares in Provalis, no investment advice is intended, all in my opinion only and I hold shares in Provalis.
Pros stock quotes
Pros stock charts
Follow this thread
